321 related articles for article (PubMed ID: 21561919)
1. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
2. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
[TBL] [Abstract][Full Text] [Related]
3. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
4. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity.
Hoffmann M; Wu YJ; Gerber M; Berger-Rentsch M; Heimrich B; Schwemmle M; Zimmer G
J Gen Virol; 2010 Nov; 91(Pt 11):2782-93. PubMed ID: 20631091
[TBL] [Abstract][Full Text] [Related]
5. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
Ammayappan A; Peng KW; Russell SJ
J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
[TBL] [Abstract][Full Text] [Related]
8. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.
Wollmann G; Davis JN; Bosenberg MW; van den Pol AN
J Virol; 2013 Jun; 87(12):6644-59. PubMed ID: 23552414
[TBL] [Abstract][Full Text] [Related]
9. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
Cary ZD; Willingham MC; Lyles DS
J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
[TBL] [Abstract][Full Text] [Related]
11. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
12. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
14. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
15. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
17. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
[TBL] [Abstract][Full Text] [Related]
18. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.
Muik A; Stubbert LJ; Jahedi RZ; Geiβ Y; Kimpel J; Dold C; Tober R; Volk A; Klein S; Dietrich U; Yadollahi B; Falls T; Miletic H; Stojdl D; Bell JC; von Laer D
Cancer Res; 2014 Jul; 74(13):3567-78. PubMed ID: 24812275
[TBL] [Abstract][Full Text] [Related]
19. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
20. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
